The agreement includes technology transfer, process validation and commercial supply of a key component of Macugen.

Detlef Rethage, president of Avecia, said: “The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances.”

Will the firms benefit with the agreement?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.